Glenmark Pharmaceuticals on May 12 said it has started Phase 3 clinical preliminaries on antiviral medication Favipiravir to check its adequacy on COVID-19 patients in India. The Mumbai-based organization had gotten endorsement from the Drug Controller General of India (DCGI) in April to lead clinical preliminaries of Favipiravir antiviral tablets for the treatment of COVID-19…